Antiphospholipid antibodies are commonly found in patients with chronic thromboembolic pulmonary hypertension and may be predictive biomarkers for the disease.
Compared with patients with a negative CT, patients with chronic thromboembolic pulmonary hypertension tended to have lower dual-energy computed tomography-based parenchymal attenuation in Hounsfield unit.
In distinct situations with clear treatment goals, such as in candidates for lung transplantation, extracorporeal membrane oxygenation should be considered.
Chronic hypoxia-exposed mice that were given fucoidans exhibited improved vascular remodeling and right ventricular function.
In patients with pulmonary arterial hypertension, endothelial colony forming cell transplantation was associated with restoration of myocardial vascular density.
LIQ861, an inhaled dry powder formulation of treprostinil, was well tolerated in patients with pulmonary arterial hypertension at a 2-week time point in the phase 3 clinical trial, INSPIRE.
Elevated levels of myocardial native T1 are associated with increased interventricular septal angle in patients with pulmonary hypertension.
PAH is an under-diagnosed complication of adult-onset Still disease.
Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial HypertensionJanuary 11, 2019
Combinations of VO2 and change in CI during follow-up visits are valuable prognosis markers in low-risk patients with PAH.
Pre-existing pulmonary hypertension does not appear to affect outcomes in transcatheter mitral valve repair with the Mitraclip device.
Systemic sclerosis-associated pulmonary hypertension and systemic sclerosis-associated interstitial lung disease exhibit similar but distinct gene expression profiles.
Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.
Patients with pulmonary hypertension age ≥65 years have worse long-term survival compared with younger patients.
Compared with the low dose, high-dose subcutaneous treprostinil increased 6-minute walk distances in patients with chronic thromboembolic pulmonary hypertension.
People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.
Because standardized approaches for echocardiographic screening are impractical for certain subgroups of people with congenital heart disease, experts offered screening adaptations for pulmonary hypertension.
Pulmonary thromboendarterectomy appears to be a curative resolution in patients with antiphospholipid syndrome related to chronic thromboembolic pulmonary hypertension.
Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.
Preterm infants who need mechanical ventilation at day 7 and early echocardiographic evidence of pulmonary vascular disease are strong risk factors for late respiratory disease.
At follow-up, the 6-minute walk distance, cardiac index, stroke volume index, and other hemodynamic variables were independently associated with transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension.
Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.
Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.
Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.
In some patients at risk for pulmonary hypertension, left ventricular end diastolic pressure measurement with standard right heart catheterization should be used.
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.
Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.